AZD4320

AZD4320 is a small molecule BH3 mimetic that acts as a dual inhibitor of the anti-apoptotic proteins BCL-2 and BCL-xL. It was developed to induce intrinsic apoptosis in cancer cells by blocking these key survival proteins, which are often upregulated in hematologic malignancies and some solid tumors. In preclinical studies, AZD4320 demonstrated potent activity against both BCL-2- and BCL-xL-dependent cell lines, with nanomolar affinity for its targets. The drug showed efficacy in models of acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and small cell lung cancer (SCLC). However, clinical development was halted due to dose-limiting cardiovascular toxicity; a dendrimer-conjugated version (AZD0466) was subsequently developed to address this issue[1][3][6][7].

Other names

UNII-LH1ZTY91ORUNII-LH-1ZTY91ORUNII-LH 1ZTY91ORLH1ZTY91ORLH-1ZTY91ORLH 1ZTY91OR